Filing Details
Pelthos Therapeutics Inc. (NYSE:PTHS) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 13, 2026.
The Healthcare company reported Q0 revenue of .
10q filedNYSE:PTHS
Pelthos Therapeutics Inc. (PTHS) Files Quarterly Report for Q0
Pelthos Therapeutics Inc. (NYSE:PTHS) filed its quarterly report (Form 10-Q) with the Securities and Exchange Commission on August 13, 2026.
At publication ·
What changed
Pelthos Therapeutics Inc. (NYSE:PTHS) · 10q filed
- Form
- 10-Q
At a glance
Key takeaways
- Pelthos Therapeutics Inc. (NYSE:PTHS) filed its Q0 quarterly report (Form 10-Q) on August 13, 2026, providing unaudited financial statements and management commentary on recent performance.
- The company's stock trades at $28.95 with a market capitalization of $15.5 million as of the filing date.
- The 10-Q filing contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last annual filing, though with less detail than the annual 10-K report.
Market Context
Pelthos Therapeutics Inc.'s stock currently trades at $28.95 with a market capitalization of $15.5M.
The 10-Q provides Pelthos Therapeutics Inc.'s quarterly financial update, including unaudited financial statements and management commentary on recent performance. While less detailed than the annual 10-K, the 10-Q often contains timely information about emerging trends, updated risk factors, and changes in business conditions since the last filing.
All SEC filings for Pelthos Therapeutics Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View PTHS Stock Page
Frequently Asked Questions
Where can I read PTHS's SEC filings?
Browse all filings on our PTHS SEC filings page.
What types of SEC filings does Pelthos Therapeutics Inc. file?
Public companies like Pelthos Therapeutics Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.